Key facts
- AIBODY’s last known valuation is $25.8M (Mar 2025).
- It has raised $7.5M; the latest was Later Stage VC ($5.8M) in Mar 2025.
- Notable investors include Northstar Ventures, DigitalHealth.London Accelerator, Google Accelerator, Raw Ventures.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for AIBODY
- ·The full record, as it builds
Funding rounds
No funding rounds for AIBODY are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About AIBODY
Developer of a cloud-based digital physiology software designed to offer real-time, immersive medical simulations. The company's software provides detailed physiological responses to virtually any simulated medical condition or treatment protocol, enabling medical professionals to speed up human physiology teaching using the digital human body and other technology systems.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2020
- Employees
- 25
- Website
- aibody.io/
- Ownership
- Privately Held (backing)
AIBODY doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in AIBODY shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on AIBODY in its N-PORT filings yet. We sweep new filings monthly.